Abstract 474P
Background
Good overall and disease-free survival for small primary lung cancers may be achieved with sublobar resections. These cancers presented as undiagnosed solitary lung nodule and may be difficult to localise intra-operatively due to their size or their ground glass nature, necessitating a greater anatomical resection. Our institution had adopted the use of image guided coil localisation since 2017 to aid the excision of such nodules. The localisation was performed on the same day just prior to the lung resection surgery. We aimed to share our experience with this technique.
Methods
We reviewed the outcomes of all patients who underwent surgical excision for undiagnosed solitary lung nodule between 2018 and 2021 and compared the efficacy with patients who had coil localisation and those who did not.
Results
182 consecutive patients were reviewed in our study. 36 patients (19.8%) underwent coil localisation whilst 146 patients (80.2%) did not. There was no significant difference in the pre-operative lung function between the 2 groups of patients. 88.5% of nodules were malignant and there was no significant difference in incidence between both groups (coil 91.7% vs no coil 87.7%, p = 0.368). Lung resection was performed via uniportal video assisted thoracoscopic (UVATS) in all coiling cases whilst 9 non-coiling cases (6.2%) had open thoracotomy. Patients who had coiling were more likely to underwent wedge resection than an anatomical resection (OR 2.14, 95% CI 1.62-2.82, p < 0.001).The conversion rate was lower in patients who had underwent coil localisation (OR 0.72, 95% CI 0.27-1.98) but this was not statistically significant (p = 0.367). All patients who underwent coil localisation reported clear margins on final histology. Patient who underwent coil localisation had a shorter length of stay (mean 3.44 +/- 2.92 days) than those who did not (mean 4.07 +/- 3.21 days) (p = 0.290). There was no significant difference in complications between both group of patients.
Conclusions
Both diagnostic and cure can be achieved via UVATS wedge resection with the aid of coil localisation. Our study demonstrated it as a safe and effective method of managing suspicious small primary lung cancers presenting as a small solitary lung nodule.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract